You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluoxetine
Accession NumberDB00472  (APRD00530)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionFluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.
Structure
Thumb
Synonyms
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
Fluoxetin
Fluoxetina
Fluoxétine
Fluoxetinum
Prozac
External Identifiers
  • Lilly 103472
  • Lilly 110 140
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-fluoxetinecapsule20 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-fluoxetinecapsule10 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-fluoxetinecapsule20 mgoralAccord Healthcare Inc2012-05-01Not applicableCanada
Ach-fluoxetinecapsule10 mgoralAccord Healthcare Inc2012-10-10Not applicableCanada
Act Fluoxetinecapsule10 mgoralDr Reddys Laboratories Inc2000-05-31Not applicableCanada
Act Fluoxetinecapsule20 mgoralDr Reddys Laboratories Inc2000-05-31Not applicableCanada
Act Fluoxetinecapsule40 mgoralDr Reddys Laboratories IncNot applicableNot applicableCanada
Auro-fluoxetinecapsule10 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-fluoxetinecapsule20 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Ava-fluoxetinecapsule20 mgoralAvanstra Inc2011-11-282014-08-21Canada
Bci Fluoxetinecapsule20 mgoralBaker Cummins IncNot applicableNot applicableCanada
Bio-fluoxetinecapsule10 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-fluoxetinecapsule20 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-fluoxetinecapsule20 mgoralDominion Pharmacal1995-12-31Not applicableCanada
Dom-fluoxetine - Cap 10mgcapsule10 mgoralDominion Pharmacal1995-12-31Not applicableCanada
Fluoxetinecapsule10 mgoralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
Fluoxetinecapsule20 mgoralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
Fluoxetinecapsule10 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Fluoxetinecapsule10 mgoralSanis Health Inc2009-10-22Not applicableCanada
Fluoxetinesolution20 mgoralAa Pharma Inc1997-06-16Not applicableCanada
Fluoxetinecapsule20 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Fluoxetinecapsule20 mgoralSanis Health Inc2009-10-22Not applicableCanada
Fluoxetine Capsulescapsule20 mgoralPharmascience Inc1999-11-10Not applicableCanada
Fluoxetine Capsulescapsule10 mgoralPharmascience Inc1999-11-10Not applicableCanada
Fluoxetine HCltablet, film coated60 mg/1oralEdgemont Pharmaceuticals, Llc2011-11-14Not applicableUs
Fluoxetine-10 - Capcapsule10 mgoralPro Doc Limitee1997-04-302010-07-13Canada
Fluoxetine-20 - Capcapsule20 mgoralPro Doc Limitee1997-04-302010-07-13Canada
Fxt 10capsule10 mgoralOryx Pharmaceuticals Inc A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc2002-11-012004-08-04Canada
Fxt 20capsule20 mgoralOryx Pharmaceuticals Inc A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc2002-11-012004-08-04Canada
Fxt 40capsule40 mgoralSepracor Pharmaceuticals Inc2002-06-212011-08-03Canada
Ipg-fluoxetinecapsule10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-fluoxetinecapsule20 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-fluoxetinecapsule10 mgoralJamp Pharma Corporation2013-04-30Not applicableCanada
Jamp-fluoxetinecapsule20 mgoralJamp Pharma Corporation2012-06-07Not applicableCanada
Mar-fluoxetinecapsule10 mgoralMarcan Pharmaceuticals Inc2013-05-07Not applicableCanada
Mar-fluoxetinecapsule20 mgoralMarcan Pharmaceuticals Inc2013-06-27Not applicableCanada
Mint-fluoxetinecapsule10 mgoralMint Pharmaceuticals Inc2012-03-20Not applicableCanada
Mint-fluoxetinecapsule20 mgoralMint Pharmaceuticals Inc2012-03-20Not applicableCanada
Mylan-fluoxetinecapsule10 mgoralMylan Pharmaceuticals Ulc1998-04-23Not applicableCanada
Mylan-fluoxetinecapsule20 mgoralMylan Pharmaceuticals Ulc1998-04-23Not applicableCanada
Nu-fluoxetinecapsule10 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Nu-fluoxetineliquid20 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-fluoxetinecapsule20 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Penta-fluoxetine Capsulescapsule20 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-fluoxetine Capsulescapsule10 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PHL-fluoxetine - Cap 10mgcapsule10 mgoralPharmel Inc1998-06-04Not applicableCanada
PHL-fluoxetine - Cap 20mgcapsule20 mgoralPharmel Inc1998-06-04Not applicableCanada
PHL-fluoxetine - Solution 20mg/5mlsolution20 mgoralPharmel Inc1998-06-04Not applicableCanada
PMS-fluox Capsules 20mgcapsule20 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-fluoxetine - Cap 10mgcapsule10 mgoralPharmascience Inc1995-12-31Not applicableCanada
PMS-fluoxetine - Cap 20mgcapsule20 mgoralPharmascience Inc1995-12-31Not applicableCanada
PMS-fluoxetine Liquid - 20mg/5mlsolution20 mgoralPharmascience Inc1997-10-20Not applicableCanada
Priva-fluoxetinecapsule20 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-fluoxetinecapsule10 mgoralPharmapar IncNot applicableNot applicableCanada
Pro-fluoxetinecapsule10 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Pro-fluoxetinecapsule20 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Prozaccapsule20 mg/1oralDista Products Company1988-02-01Not applicableUs
Prozaccapsule40 mg/1oralDista Products Company1999-06-15Not applicableUs
Prozaccapsule20 mg/1oralStat Rx USA1987-12-29Not applicableUs
Prozaccapsule10 mg/1oralDista Products Company1993-01-13Not applicableUs
Prozac Capsules 10mgcapsule10 mgoralEli Lilly Canada Inc1993-12-31Not applicableCanada
Prozac Capsules 20mgcapsule20 mgoralEli Lilly Canada Inc1989-12-31Not applicableCanada
Prozac Liq 20mg/5mlliquid20 mgoralEli Lilly Canada Inc1992-12-312007-08-29Canada
Prozac Weeklycapsule, delayed release90 mg/1oralEli Lilly and Company2001-03-16Not applicableUs
Q-fluoxetinecapsule20 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-fluoxetinecapsule10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-fluoxetinecapsule10 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-08Not applicableCanada
Ran-fluoxetinecapsule20 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-08Not applicableCanada
Ratio-fluoxetinecapsule10 mgoralRatiopharm Inc Division Of Teva Canada Limited2000-01-242014-09-19Canada
Ratio-fluoxetinecapsule20 mgoralRatiopharm Inc Division Of Teva Canada Limited2000-01-242014-09-19Canada
Riva-fluoxetinecapsule10 mgoralLaboratoire Riva Inc2010-10-22Not applicableCanada
Riva-fluoxetinecapsule20 mgoralLaboratoire Riva Inc2000-05-232013-07-31Canada
Riva-fluoxetinecapsule20 mgoralLaboratoire Riva Inc2009-09-21Not applicableCanada
Riva-fluoxetinecapsule10 mgoralLaboratoire Riva Inc2000-05-232014-07-29Canada
Sandoz Fluoxetinecapsule10 mgoralSandoz Canada Incorporated2001-02-22Not applicableCanada
Sandoz Fluoxetinecapsule20 mgoralSandoz Canada Incorporated2001-02-22Not applicableCanada
Sarafemtablet10 mg/1oralWarner Chilcott (US), LLC2008-06-24Not applicableUs
Sarafemtablet20 mg/1oralWarner Chilcott (US), LLC2008-06-24Not applicableUs
Stcc-fluoxetine - Cap 10mgcapsule10 mgoralStcc Inc.1995-12-312002-07-31Canada
Stcc-fluoxetine - Cap 20mgcapsule20 mgoralStcc Inc.1995-12-312002-07-31Canada
Teva-fluoxetinecapsule20 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Teva-fluoxetinecapsule10 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Van-fluoxetinecapsule10 mgoralVanc Pharmaceuticals Inc2015-07-07Not applicableCanada
Van-fluoxetinecapsule20 mgoralVanc Pharmaceuticals Inc2015-07-07Not applicableCanada
Zym-fluoxetinecapsule10 mgoralZymcan Pharmaceuticals Inc2009-02-262014-06-16Canada
Zym-fluoxetinecapsule20 mgoralZymcan Pharmaceuticals Inc2009-02-262014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluoxetinecapsule20 mgoralApotex Inc1996-12-31Not applicableCanada
Apo-fluoxetinecapsule10 mgoralApotex Inc1996-12-31Not applicableCanada
Fluoxetinecapsule20 mg/1oralMc Kesson Contract Packaging2011-10-17Not applicableUs
Fluoxetinecapsule10 mg/1oralMajor Pharmaceuticals2007-02-16Not applicableUs
Fluoxetinecapsule20 mg/1oralRebel Distributors Corp2002-01-29Not applicableUs
Fluoxetinetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2013-12-23Not applicableUs
Fluoxetinecapsule20 mg/1oralUnit Dose Services2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralCardinal Health2013-02-04Not applicableUs
Fluoxetinetablet, film coated10 mg/1oralProficient Rx LP2002-01-30Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Vantx, Inc.2012-03-20Not applicableUs
Fluoxetinecapsule20 mg/1oralReady Meds2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralAmerican Health Packaging2013-12-10Not applicableUs
Fluoxetinecapsule40 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralSTAT Rx USA LLC2010-04-29Not applicableUs
Fluoxetinecapsule40 mg/1oralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
Fluoxetinecapsule40 mg/1oralTeva Pharmaceuticals USA Inc2012-08-29Not applicableUs
Fluoxetinecapsule20 mg/1oralPliva Inc.2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2013-02-252016-04-05Us
Fluoxetinecapsule20 mg/1oralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
Fluoxetinecapsule20 mg/1oralCarlsbad Technology, Inc.2002-01-30Not applicableUs
Fluoxetinecapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-19Not applicableUs
Fluoxetinecapsule20 mg/1oralBarr Laboratories Inc.2001-08-02Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Health Pharma, LLC2011-01-15Not applicableUs
Fluoxetinecapsule10 mg/1oralClinical Solutions Wholesale2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralbryant ranch prepack2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralBlenheim Pharmacal, Inc.2009-12-22Not applicableUs
Fluoxetinecapsule40 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Fluoxetinecapsule20 mg/1oralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinesolution20 mg/5mLoralPharmaceutical Associates, Inc.2002-01-30Not applicableUs
Fluoxetinecapsule10 mg/1oralAv Pak2014-08-20Not applicableUs
Fluoxetinecapsule10 mg/1oralCardinal Health2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralProficient Rx LP2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralAurobindo Pharma Limited2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralPreferred Pharmaceuticals, Inc.2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralRebel Distributors Corp2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralProficient Rx LP2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Vantx, Inc.2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralMc Kesson Contract Packaging2012-04-16Not applicableUs
Fluoxetinecapsule20 mg/1oralMajor Pharmaceuticals2007-02-16Not applicableUs
Fluoxetinetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2013-12-23Not applicableUs
Fluoxetinecapsule40 mg/1oralUnit Dose Services2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralPd Rx Pharmaceuticals, Inc.2002-01-29Not applicableUs
Fluoxetinecapsule40 mg/1oralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
Fluoxetinecapsule10 mg/1oralTYA Pharmaceuticals2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralAmerican Health Packaging2013-02-04Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2016-02-25Not applicableUs
Fluoxetinecapsule10 mg/1oralNorth Star Rx Llc2009-07-01Not applicableUs
Fluoxetinecapsule20 mg/1oralAidarex Pharmaceuticals LLC2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2008-01-31Not applicableUs
Fluoxetinesolution20 mg/5mLoralTeva Pharmaceuticals USA Inc2001-08-02Not applicableUs
Fluoxetinecapsule10 mg/1oralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule10 mg/1oralREMEDYREPACK INC.2013-02-262016-04-05Us
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Fluoxetinecapsule40 mg/1oralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-05-24Not applicableUs
Fluoxetinecapsule20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-29Not applicableUs
Fluoxetinecapsule40 mg/1oralMed Health Pharma, LLC2011-01-15Not applicableUs
Fluoxetinecapsule20 mg/1oralClinical Solutions Wholesale2002-01-29Not applicableUs
Fluoxetinecapsule40 mg/1oralbryant ranch prepack2008-12-08Not applicableUs
Fluoxetinecapsule20 mg/1oralContract Pharmacy Services Pa2011-01-25Not applicableUs
Fluoxetinecapsule10 mg/1oralBlenheim Pharmacal, Inc.2009-12-22Not applicableUs
Fluoxetinecapsule20 mg/1oralRebel Distributors Corp2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2008-01-31Not applicableUs
Fluoxetinesolution20 mg/5mLoralPharmaceutical Associates, Inc.2002-02-01Not applicableUs
Fluoxetinecapsule20 mg/1oralAv Pak2014-08-20Not applicableUs
Fluoxetinecapsule10 mg/1oralState of Florida DOH Central Pharmacy2012-06-01Not applicableUs
Fluoxetinecapsule20 mg/1oralCardinal Health2011-07-11Not applicableUs
Fluoxetinecapsule10 mg/1oralProficient Rx LP2008-01-31Not applicableUs
Fluoxetinecapsule40 mg/1oralAurobindo Pharma Limited2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralPreferred Pharmaceuticals, Inc.2008-01-31Not applicableUs
Fluoxetineliquid20 mg/5mLoralSilarx Pharmaceuticals, Inc2009-08-27Not applicableUs
Fluoxetinecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2002-10-15Not applicableUs
Fluoxetinecapsule40 mg/1oralRanbaxy Pharmaceuticals Inc.2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralMed Vantx, Inc.2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralProdigy Health Supplier2012-06-01Not applicableUs
Fluoxetinecapsule20 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Fluoxetinecapsule10 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Fluoxetinecapsule10 mg/1oralUnit Dose Services2008-01-31Not applicableUs
Fluoxetinetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2002-01-30Not applicableUs
Fluoxetinecapsule20 mg/1oralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule10 mg/1oralREMEDYREPACK INC.2013-05-09Not applicableUs
Fluoxetinecapsule20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Fluoxetinecapsule20 mg/1oralTYA Pharmaceuticals2008-01-31Not applicableUs
Fluoxetinecapsule20 mg/1oralLegacy Pharmaceutical Packaging2011-01-25Not applicableUs
Fluoxetinecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2002-01-29Not applicableUs
Fluoxetinecapsule20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-20Not applicableUs
Fluoxetinecapsule20 mg/1oralNorth Star Rx Llc2009-07-01Not applicableUs
Fluoxetinecapsule10 mg/1oralAidarex Pharmaceuticals LLC2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
Fluoxetinecapsule20 mg/1oralSTAT Rx USA LLC2012-03-20Not applicableUs
Fluoxetinecapsule40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Fluoxetinecapsule10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-05-20Not applicableUs
Fluoxetinecapsule10 mg/1oralPhysicians Total Care, Inc.2007-11-28Not applicableUs
Fluoxetinesolution20 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2002-08-29Not applicableUs
Fluoxetinecapsule20 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-18Not applicableUs
Fluoxetinecapsule10 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Fluoxetinecapsule40 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Fluoxetinecapsule40 mg/1oralRebel Distributors Corp2005-07-20Not applicableUs
Fluoxetinecapsule40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2014-11-06Not applicableUs
Fluoxetinecapsule40 mg/1oralAv Pak2014-08-20Not applicableUs
Fluoxetinecapsule10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Fluoxetinecapsule10 mg/1oralCardinal Health2007-02-16Not applicableUs
Fluoxetinecapsule40 mg/1oralProficient Rx LP2005-07-20Not applicableUs
Fluoxetinesolution20 mg/5mLoralAurobindo Pharma Limited2009-03-19Not applicableUs
Fluoxetinecapsule20 mg/1oralLife Line Home Care Services, Inc.2012-01-16Not applicableUs
Fluoxetinecapsule10 mg/1oralMed Health Pharma, LLC2011-01-15Not applicableUs
Fluoxetinecapsule40 mg/1oralClinical Solutions Wholesale2005-07-20Not applicableUs
Fluoxetinecapsule10 mg/1oralbryant ranch prepack2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralContract Pharmacy Services Pa2010-07-30Not applicableUs
Fluoxetinecapsule20 mg/1oralProdigy Health Supplier2012-06-01Not applicableUs
Fluoxetinecapsule10 mg/1oralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Fluoxetinecapsule20 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Fluoxetinecapsule10 mg/1oralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule40 mg/1oralPar Pharmaceutical Companies, Inc.2008-12-08Not applicableUs
Fluoxetinecapsule40 mg/1oralTeva Pharmaceuticals USA Inc2002-01-30Not applicableUs
Fluoxetinecapsule40 mg/1oralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
Fluoxetinecapsule20 mg/1oralREMEDYREPACK INC.2013-06-032016-04-05Us
Fluoxetinecapsule20 mg/1oralCardinal Health2007-02-16Not applicableUs
Fluoxetinecapsule10 mg/1oralAurobindo Pharma Limited2008-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralLegacy Pharmaceutical Packaging2011-01-31Not applicableUs
Fluoxetinecapsule10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-20Not applicableUs
Fluoxetinecapsule40 mg/1oralNorth Star Rx Llc2009-07-01Not applicableUs
Fluoxetinecapsule40 mg/1oralAidarex Pharmaceuticals LLC2005-07-20Not applicableUs
Fluoxetinecapsule20 mg/1oralMedsource Pharmaceuticals2009-06-09Not applicableUs
Fluoxetinecapsule10 mg/1oralSTAT Rx USA LLC2012-03-20Not applicableUs
Fluoxetinecapsule20 mg/1oralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
Fluoxetinecapsule40 mg/1oralPd Rx Pharmaceuticals, Inc.2008-12-08Not applicableUs
Fluoxetinecapsule10 mg/1oralPliva Inc.2002-01-29Not applicableUs
Fluoxetinecapsule10 mg/1oralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
Fluoxetinecapsule10 mg/1oralCarlsbad Technology, Inc.2002-01-30Not applicableUs
Fluoxetinecapsule40 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-18Not applicableUs
Fluoxetinecapsule40 mg/1oralBlue Point Laboratories2013-12-23Not applicableUs
Fluoxetinecapsule20 mg/1oralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
Fluoxetine HClcapsule40 mg/1oralDIRECT RX2015-01-01Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralRebel Distributors Corp2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Fluoxetine Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2001-08-02Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2003-08-19Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralContract Pharmacy Services Pa2010-04-05Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2011-07-21Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralSandoz Inc2002-01-29Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralRebel Distributors Corp2010-01-13Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralAv Kare, Inc.2012-08-30Not applicableUs
Fluoxetine Hydrochloridetablet, film coated10 mg/1oralPar Pharmaceutical, Inc2001-08-02Not applicableUs
Fluoxetine Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-13Not applicableUs
Fluoxetine Hydrochloridecapsule40 mg/1oralPhysicians Total Care, Inc.2008-07-25Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2010-12-21Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralSandoz Inc2001-08-02Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralAv Kare, Inc.2012-08-30Not applicableUs
Fluoxetine Hydrochloridetablet, film coated20 mg/1oralPar Pharmaceutical, Inc2001-08-02Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralMylan Pharmaceuticals Inc.2008-11-17Not applicableUs
Fluoxetine Hydrochloridecapsule, delayed release pellets90 mg/1oralDr.Reddy's Laboratories Limited2010-03-24Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralAphena Pharma Solutions Tennessee, Inc.2001-08-02Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralNorthwind Pharmaceuticals2014-05-20Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule40 mg/1oralSandoz Inc2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralKAISER FOUNDATION HOSPITALS2010-04-14Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralMylan Pharmaceuticals Inc.2008-11-17Not applicableUs
Fluoxetine Hydrochloridecapsule20 mg/1oralPhysicians Total Care, Inc.2008-10-23Not applicableUs
Fluoxetine Hydrochloridecapsule40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-01-29Not applicableUs
Fluoxetine Hydrochloridecapsule10 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdofenBrainpharma
Animex-OnLaboratorios
FluoxerenMenarini
FontexLilly
LadoseLilly
Brand mixtures
NameLabellerIngredients
GaboxetinePhysician Therapeutics Llc
Olanzapine and FluoxetineTeva Pharmaceuticals USA Inc
Sentraflox Am-10Physician Therapeutics Llc
SentroxatinePhysician Therapeutics Llc
SymbyaxEli Lilly and Company
Salts
Name/CASStructureProperties
Fluoxetine Hydrochloride
Thumb
  • InChI Key: GIYXAJPCNFJEHY-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.110726557
  • Average Mass: 345.787
DBSALT000087
Categories
UNII01K63SUP8D
CAS number54910-89-3
WeightAverage: 309.3261
Monoisotopic: 309.134048818
Chemical FormulaC17H18F3NO
InChI KeyInChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
IUPAC Name
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
SMILES
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenol ether
  • Aralkylamine
  • Alkyl aryl ether
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationLabeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.
PharmacodynamicsFluoxetine, an antidepressant agent belonging to the selective serotonin reuptake inhibitors (SSRIs), is used to treat depression, bulimia nervosa, premenstrual dysphoric disorder, panic disorder and post-traumatic stress. According to the amines hypothesis, a functional decrease in the activity of amines, such as serotonin and norepinephrine, would result in depression; a functional increase of the activity of these amines would result in mood elevation. Fluoxetine's effects are thought to be associated with the inhibition of 5HT receptor, which leads to an increase of serotonin level. Antagonism of muscarinic, histaminergic, and α1–adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.
Mechanism of actionMetabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake inhibitor (SSRI), it blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionWell absorbed from the GI tract following oral administration. Oral bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-8 hours following a single oral administration of a 40 mg dose. The oral solution and delayed-release capsule are bioequivalent. Food does not affect the systemic bioavailability of fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). Prozac Weekly capsules, a delayed–release formulation, contain enteric–coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediate–release formulations.
Volume of distribution
  • 20-45 L/kg
Protein binding94.5% bound to human serum proteins, including albumin and alpha-1-glycoprotein.
Metabolism

Limited data from animal studies suggest that fluoxetine may undergo first-pass metabolism may occur via the liver and/or lungs. Fluoxetine appears to be extensively metabolized, likely in the liver, to norfluoxetine and other metabolites. Norfluoxetine, the principal active metabolite, is formed via N-demethylation of fluoxetine. Norfluoxetine appears to be comparable pharmacologic potency as fluoxetine. Fluoxetine and norfluoxetine both undergo phase II glucuronidation reactions in the liver. It is also thought that fluoxetine and norfluoxetine undergo O-dealkylation to form p-trifluoromethylphenol, which is then subsequently metabolized to hippuric acid.

SubstrateEnzymesProduct
Fluoxetine
NorfluoxetineDetails
Fluoxetine
para-TrifluoromethylphenolDetails
Fluoxetine
Hippuric acidDetails
Fluoxetine
Fluoxetine glucuronideDetails
Norfluoxetine
Norfluoxetine glucuronideDetails
Norfluoxetine
Not Available
Norfluoxetine alcoholDetails
Norfluoxetine alcohol
Not Available
Norfluoxetine acidDetails
Route of eliminationThe primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney. The S-enantiomer is eliminated more slowly and is the predominant enantiomer present at steady state.
Half life1-3 days [acute administration]; 4-6 days [chronic administration]; 4-16 days [norfluoxetine, acute and chronic administration].
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, restlessness, hypomania, and other signs of CNS excitation. LD50=284mg/kg (orally in mice). The most frequent side effects include: nervous system effects such as anxiety, nervousness, insomnia, drowsiness, fatigue or asthenia, tremor, and dizziness or lightheadedness; GI effects such as anorexia, nausea, and diarrhea; vasodilation; dry mouth; abnormal vision; decreased libido; abnormal ejaculation; rash; and sweating. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fluoxetine Action PathwayDrug actionSMP00426
Fluoxetine Metabolism PathwayDrug metabolismSMP00646
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.983
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5899
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.5459
Renal organic cation transporterInhibitor0.5633
CYP450 2C9 substrateNon-substrate0.7475
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7149
Ames testNon AMES toxic0.7105
CarcinogenicityNon-carcinogens0.8089
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity2.6048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6058
hERG inhibition (predictor II)Inhibitor0.8467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Dr reddys laboratories ltd
  • Eli lilly and co
  • Mutual pharmacal co
  • Watson laboratories inc
  • Alembic ltd
  • Alphapharm party ltd
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Carlsbad technology inc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Landela pharmaceutical
  • Mallinckrodt inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Lilly research laboratories div eli lilly and co
  • Actavis mid atlantic llc
  • Aurobindo pharma usa inc
  • Hi tech pharmacal co inc
  • Lannett holdings inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Warner chilcott inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral40 mg/1
Liquidoral20 mg/5mL
Solutionoral20 mg/5mL
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral60 mg/1
Capsuleoral10 mg/1
Capsuleoral20 mg/1
Capsule, delayed release pelletsoral90 mg/1
Capsuleoral40 mg
Kit
Solutionoral20 mg
Capsuleoral20 mg
Capsuleoral10 mg
Liquidoral20 mg
Capsule, delayed releaseoral90 mg/1
Tabletoral10 mg/1
Tabletoral20 mg/1
Capsuleoral
Prices
Unit descriptionCostUnit
PROzac 20 mg/5ml Solution 120ml Bottle266.51USD bottle
PROzac Weekly 1 Package = 4 capsule (90 mg) Disp Pack140.77USD disp
Sarafem 7 10 mg tablet Box61.08USD box
Sarafem 7 20 mg tablet Each Box Contains 7 tablet59.55USD box
Prozac weekly 90 mg capsule34.5USD capsule
PROzac 40 mg capsule13.89USD capsule
Fluoxetine hcl powder8.32USD g
Sarafem 10 mg tablet7.91USD tablet
Sarafem 15 mg tablet7.91USD tablet
Sarafem 20 mg tablet7.91USD tablet
PROzac 20 mg capsule6.95USD capsule
PROzac 10 mg capsule6.77USD capsule
FLUoxetine HCl 40 mg capsule5.54USD capsule
PROzac 10 mg tablet4.31USD tablet
Fluoxetine hcl 20 mg tablet4.26USD tablet
Rapiflux 20 mg tablet3.11USD tablet
FLUoxetine HCl 20 mg capsule2.77USD capsule
Fluoxetine hcl 10 mg tablet2.72USD tablet
FLUoxetine HCl 10 mg capsule2.7USD capsule
Fxt 40 40 mg Capsule2.3USD capsule
Prozac 10 mg Capsule2.02USD capsule
Prozac 20 mg Capsule2.02USD capsule
Apo-Fluoxetine 10 mg Capsule1.13USD capsule
Co Fluoxetine 10 mg Capsule1.13USD capsule
Mylan-Fluoxetine 10 mg Capsule1.13USD capsule
Novo-Fluoxetine 10 mg Capsule1.13USD capsule
Nu-Fluoxetine 10 mg Capsule1.13USD capsule
Phl-Fluoxetine 10 mg Capsule1.13USD capsule
Pms-Fluoxetine 10 mg Capsule1.13USD capsule
Ratio-Fluoxetine Hydrochloride 10 mg Capsule1.13USD capsule
Sandoz Fluoxetine 10 mg Capsule1.13USD capsule
Apo-Fluoxetine 20 mg Capsule1.06USD capsule
Co Fluoxetine 20 mg Capsule1.06USD capsule
Mylan-Fluoxetine 20 mg Capsule1.06USD capsule
Novo-Fluoxetine 20 mg Capsule1.06USD capsule
Nu-Fluoxetine 20 mg Capsule1.06USD capsule
Phl-Fluoxetine 20 mg Capsule1.06USD capsule
Pms-Fluoxetine 20 mg Capsule1.06USD capsule
Ratio-Fluoxetine Hydrochloride 20 mg Capsule1.06USD capsule
Sandoz Fluoxetine 20 mg Capsule1.06USD capsule
FLUoxetine HCl 20 mg/5ml Solution1.03USD ml
Apo-Fluoxetine 4 mg/ml Liquid0.61USD liquid
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5910319 Yes1997-11-292017-11-29Us
US5945416 No1997-03-242017-03-24Us
US5985322 Yes1997-11-292017-11-29Us
US6960577 No1997-11-012017-11-01Us
USRE39030 No1997-05-292017-05-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point179-182 °CNot Available
water solubility50 mg/mL at 25 °CNot Available
logP4.05ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0017 mg/mLALOGPS
logP4.09ALOGPS
logP4.17ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity80.37 m3·mol-1ChemAxon
Polarizability30.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9200000000-dcf68dbfd090c7fdfe11View in MoNA
References
Synthesis Reference

Eduard Schwartz, Joseph Kaspi, Zinovi Itov, Gidon Pilarski, “Production of fluoxetine and new intermediates.” U.S. Patent US5225585, issued October, 1990.

US5225585
General References
  1. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411-41. [PubMed:7623609 ]
  2. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB: A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471-9. [PubMed:4549929 ]
  3. Carlsson A, Wong DT: Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 1997;61(12):1203. [PubMed:9315511 ]
  4. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998 Jun;32(6):692-8. [PubMed:9640489 ]
  5. Caley CF: Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997 Dec;31(12):1481-9. [PubMed:9416386 ]
External Links
ATC CodesN06CA03N06AB03
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (194 KB)
MSDSDownload (76.7 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluoxetine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluoxetine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Fluoxetine.
AbirateroneThe serum concentration of Fluoxetine can be increased when it is combined with Abiraterone.
AcarboseFluoxetine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.
AcenocoumarolFluoxetine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluoxetine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fluoxetine.
AcetophenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Fluoxetine.
Acetylsalicylic acidFluoxetine may increase the antiplatelet activities of Acetylsalicylic acid.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Fluoxetine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fluoxetine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluoxetine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluoxetine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Fluoxetine.
AlbiglutideFluoxetine may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluoxetine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluoxetine.
AlfentanilAlfentanil may increase the serotonergic activities of Fluoxetine.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Fluoxetine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluoxetine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluoxetine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluoxetine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Fluoxetine.
AlogliptinFluoxetine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Fluoxetine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluoxetine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Fluoxetine.
AmantadineAmantadine may increase the QTc-prolonging activities of Fluoxetine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fluoxetine.
AmineptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluoxetine.
AmiodaroneFluoxetine may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluoxetine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluoxetine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fluoxetine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluoxetine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluoxetine.
AmoxapineFluoxetine may increase the serotonergic activities of Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Fluoxetine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluoxetine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Fluoxetine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluoxetine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Fluoxetine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Fluoxetine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluoxetine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fluoxetine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Fluoxetine.
AprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Fluoxetine.
AprindineThe metabolism of Aprindine can be decreased when combined with Fluoxetine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Fluoxetine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Fluoxetine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluoxetine.
ArmodafinilThe metabolism of Fluoxetine can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.
Arsenic trioxideFluoxetine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherFluoxetine may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluoxetine.
AsenapineFluoxetine may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Fluoxetine.
AtazanavirThe metabolism of Fluoxetine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Fluoxetine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluoxetine.
AtomoxetineThe metabolism of Fluoxetine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fluoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluoxetine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluoxetine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Fluoxetine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Fluoxetine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluoxetine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Fluoxetine.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Fluoxetine.
BendroflumethiazideFluoxetine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Fluoxetine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Fluoxetine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluoxetine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluoxetine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Fluoxetine.
BepridilThe metabolism of Bepridil can be decreased when combined with Fluoxetine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluoxetine.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Fluoxetine.
BetaxololThe metabolism of Fluoxetine can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.
BexaroteneThe serum concentration of Fluoxetine can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Fluoxetine.
BifeprunoxThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Fluoxetine.
BoceprevirThe metabolism of Fluoxetine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Fluoxetine.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.
BortezomibThe metabolism of Fluoxetine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Fluoxetine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluoxetine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fluoxetine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluoxetine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluoxetine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Fluoxetine.
BromocriptineFluoxetine may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluoxetine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fluoxetine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluoxetine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluoxetine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Fluoxetine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluoxetine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Fluoxetine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Fluoxetine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Fluoxetine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluoxetine.
BupropionThe metabolism of Bupropion can be decreased when combined with Fluoxetine.
BuserelinBuserelin may increase the QTc-prolonging activities of Fluoxetine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluoxetine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Fluoxetine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fluoxetine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluoxetine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fluoxetine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluoxetine.
ButorphanolButorphanol may increase the serotonergic activities of Fluoxetine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fluoxetine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluoxetine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Fluoxetine.
CaffeineThe metabolism of Fluoxetine can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluoxetine.
CanagliflozinFluoxetine may increase the hypoglycemic activities of Canagliflozin.
CapecitabineThe metabolism of Fluoxetine can be decreased when combined with Capecitabine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Fluoxetine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluoxetine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Fluoxetine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fluoxetine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluoxetine.
CarfentanilCarfentanil may increase the serotonergic activities of Fluoxetine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluoxetine.
CariprazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluoxetine.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Fluoxetine.
CaroxazoneCaroxazone may increase the serotonergic activities of Fluoxetine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Fluoxetine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Fluoxetine.
CelecoxibThe metabolism of Fluoxetine can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Fluoxetine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Fluoxetine.
CeritinibCeritinib may increase the QTc-prolonging activities of Fluoxetine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Fluoxetine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluoxetine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluoxetine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Fluoxetine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluoxetine.
ChloramphenicolThe metabolism of Fluoxetine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluoxetine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Fluoxetine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluoxetine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluoxetine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Fluoxetine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Fluoxetine.
ChlorothiazideFluoxetine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluoxetine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Fluoxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorpromazine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Fluoxetine.
ChlorpropamideFluoxetine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluoxetine.
ChlorthalidoneFluoxetine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluoxetine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Fluoxetine.
CholecalciferolThe metabolism of Fluoxetine can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Fluoxetine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fluoxetine.
CimetidineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Fluoxetine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluoxetine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluoxetine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Fluoxetine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fluoxetine.
CisaprideFluoxetine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluoxetine.
CitalopramCitalopram may increase the QTc-prolonging activities of Fluoxetine.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Fluoxetine.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Fluoxetine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fluoxetine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluoxetine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fluoxetine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fluoxetine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fluoxetine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Fluoxetine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fluoxetine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fluoxetine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Fluoxetine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluoxetine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluoxetine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Fluoxetine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Fluoxetine.
ClopidogrelThe metabolism of Fluoxetine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Fluoxetine.
ClotrimazoleThe metabolism of Fluoxetine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clozapine.
ClozapineClozapine may increase the QTc-prolonging activities of Fluoxetine.
CobicistatThe serum concentration of Fluoxetine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluoxetine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluoxetine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.
CodeineCodeine may increase the serotonergic activities of Fluoxetine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluoxetine.
ConivaptanThe serum concentration of Fluoxetine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fluoxetine.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Fluoxetine.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Fluoxetine.
CyamemazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluoxetine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.
CyclosporineThe metabolism of Fluoxetine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fluoxetine.
CyproheptadineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.
Cyproterone acetateThe serum concentration of Fluoxetine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluoxetine.
DabrafenibThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Fluoxetine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluoxetine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.
DapagliflozinFluoxetine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluoxetine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.
DapoxetineFluoxetine may increase the serotonergic activities of Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluoxetine.
DarifenacinThe metabolism of Fluoxetine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Fluoxetine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Fluoxetine.
DasatinibThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fluoxetine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fluoxetine.
DeferasiroxThe serum concentration of Fluoxetine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Fluoxetine.
DelavirdineThe metabolism of Fluoxetine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fluoxetine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluoxetine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluoxetine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Fluoxetine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluoxetine.
DesmopressinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluoxetine.
DexamethasoneThe serum concentration of Fluoxetine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Fluoxetine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Fluoxetine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluoxetine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Fluoxetine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Fluoxetine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluoxetine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Fluoxetine.
DextromoramideDextromoramide may increase the serotonergic activities of Fluoxetine.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Fluoxetine.
DezocineDezocine may increase the serotonergic activities of Fluoxetine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluoxetine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fluoxetine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluoxetine.
DicoumarolFluoxetine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluoxetine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fluoxetine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fluoxetine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fluoxetine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Fluoxetine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Fluoxetine.
DihydroergotamineThe metabolism of Fluoxetine can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Fluoxetine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Fluoxetine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fluoxetine.
DiltiazemThe metabolism of Fluoxetine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Fluoxetine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluoxetine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluoxetine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Fluoxetine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Fluoxetine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluoxetine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Fluoxetine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fluoxetine.
DofetilideDofetilide may increase the QTc-prolonging activities of Fluoxetine.
DolasetronDolasetron may increase the QTc-prolonging activities of Fluoxetine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Fluoxetine.
DomperidoneFluoxetine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluoxetine.
DopamineThe metabolism of Dopamine can be decreased when combined with Fluoxetine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluoxetine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fluoxetine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Fluoxetine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluoxetine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Fluoxetine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluoxetine.
DoxorubicinThe metabolism of Fluoxetine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Fluoxetine can be decreased when combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Fluoxetine.
DPDPEDPDPE may increase the serotonergic activities of Fluoxetine.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Fluoxetine.
DronedaroneFluoxetine may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Droperidol.
DroperidolDroperidol may increase the QTc-prolonging activities of Fluoxetine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluoxetine.
DulaglutideFluoxetine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.
DuloxetineThe metabolism of Fluoxetine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluoxetine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fluoxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluoxetine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fluoxetine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Fluoxetine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluoxetine.
EliglustatFluoxetine may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinFluoxetine may increase the hypoglycemic activities of Empagliflozin.
EncainideThe metabolism of Encainide can be decreased when combined with Fluoxetine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Fluoxetine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluoxetine.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Fluoxetine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluoxetine.
EnzalutamideThe serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Fluoxetine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Fluoxetine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fluoxetine.
ErythromycinErythromycin may increase the QTc-prolonging activities of Fluoxetine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Fluoxetine.
EscitalopramFluoxetine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Fluoxetine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Esmirtazapine.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Fluoxetine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Fluoxetine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluoxetine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fluoxetine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluoxetine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Fluoxetine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluoxetine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluoxetine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluoxetine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.
Ethyl biscoumacetateFluoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluoxetine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Fluoxetine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Fluoxetine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fluoxetine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluoxetine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluoxetine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.
EtoperidoneFluoxetine may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fluoxetine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluoxetine.
EtorphineEtorphine may increase the serotonergic activities of Fluoxetine.
EtravirineThe serum concentration of Fluoxetine can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Fluoxetine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.
ExenatideFluoxetine may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluoxetine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Fluoxetine.
FamotidineFamotidine may increase the QTc-prolonging activities of Fluoxetine.
FamotidineThe metabolism of Famotidine can be decreased when combined with Fluoxetine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fluoxetine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluoxetine.
FenfluramineFluoxetine may increase the serotonergic activities of Fenfluramine.
FentanylFentanyl may increase the serotonergic activities of Fluoxetine.
FentanylThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fluoxetine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fluoxetine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluoxetine.
FingolimodFingolimod may increase the QTc-prolonging activities of Fluoxetine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Fluoxetine.
FlecainideFlecainide may increase the QTc-prolonging activities of Fluoxetine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Fluoxetine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluoxetine.
FloxuridineThe metabolism of Fluoxetine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Fluoxetine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluoxetine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluoxetine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluoxetine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluoxetine.
FluorouracilThe metabolism of Fluoxetine can be decreased when combined with Fluorouracil.
FlupentixolFluoxetine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluoxetine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluoxetine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Fluoxetine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluoxetine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fluoxetine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluoxetine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluoxetine.
FluvoxamineFluoxetine may increase the serotonergic activities of Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Fluoxetine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Fluoxetine.
FosamprenavirThe metabolism of Fluoxetine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Fluoxetine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fluoxetine.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Fluoxetine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluoxetine.
FrovatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Fluoxetine.
Fusidic AcidThe serum concentration of Fluoxetine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluoxetine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Fluoxetine.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Fluoxetine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.
GalantamineGalantamine may increase the QTc-prolonging activities of Fluoxetine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluoxetine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fluoxetine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fluoxetine.
GemfibrozilThe metabolism of Fluoxetine can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Fluoxetine.
GliclazideFluoxetine may increase the hypoglycemic activities of Gliclazide.
GlimepirideFluoxetine may increase the hypoglycemic activities of Glimepiride.
GlipizideFluoxetine may increase the hypoglycemic activities of Glipizide.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Fluoxetine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluoxetine.
GlyburideFluoxetine may increase the hypoglycemic activities of Glyburide.
GoserelinGoserelin may increase the QTc-prolonging activities of Fluoxetine.
GranisetronGranisetron may increase the QTc-prolonging activities of Fluoxetine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Fluoxetine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluoxetine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fluoxetine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluoxetine.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluoxetine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Fluoxetine.
HaloperidolFluoxetine may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluoxetine.
HalothaneThe metabolism of Halothane can be decreased when combined with Fluoxetine.
HeroinHeroin may increase the serotonergic activities of Fluoxetine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluoxetine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluoxetine.
HistrelinHistrelin may increase the QTc-prolonging activities of Fluoxetine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Fluoxetine.
HydrochlorothiazideFluoxetine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.
HydrocodoneHydrocodone may increase the serotonergic activities of Fluoxetine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fluoxetine.
HydroflumethiazideFluoxetine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Fluoxetine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluoxetine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Fluoxetine.
IbandronateIbandronate may increase the QTc-prolonging activities of Fluoxetine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Fluoxetine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fluoxetine.
IbutilideIbutilide may increase the QTc-prolonging activities of Fluoxetine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluoxetine.
IdelalisibThe serum concentration of Fluoxetine can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Fluoxetine.
IloperidoneFluoxetine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Fluoxetine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Fluoxetine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluoxetine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fluoxetine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Fluoxetine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Fluoxetine.
IndalpineFluoxetine may increase the serotonergic activities of Indalpine.
IndapamideFluoxetine may increase the hyponatremic activities of Indapamide.
IndapamideIndapamide may increase the QTc-prolonging activities of Fluoxetine.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Fluoxetine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Fluoxetine.
IndinavirThe metabolism of Fluoxetine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fluoxetine.
Insulin AspartFluoxetine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirFluoxetine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineFluoxetine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineFluoxetine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanFluoxetine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproFluoxetine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Fluoxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.
IproclozideIproclozide may increase the serotonergic activities of Fluoxetine.
IproniazidIproniazid may increase the serotonergic activities of Fluoxetine.
IrbesartanThe metabolism of Fluoxetine can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fluoxetine.
IsavuconazoniumThe metabolism of Fluoxetine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Fluoxetine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluoxetine.
IsoniazidThe metabolism of Fluoxetine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Fluoxetine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Fluoxetine can be decreased when combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Fluoxetine.
IvacaftorThe serum concentration of Fluoxetine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fluoxetine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluoxetine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluoxetine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fluoxetine.
KetobemidoneKetobemidone may increase the serotonergic activities of Fluoxetine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluoxetine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Fluoxetine.
KetoconazoleThe metabolism of Fluoxetine can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluoxetine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Fluoxetine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluoxetine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluoxetine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fluoxetine.
LanreotideFluoxetine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fluoxetine.
LapatinibLapatinib may increase the QTc-prolonging activities of Fluoxetine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Fluoxetine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluoxetine.
LeflunomideThe metabolism of Fluoxetine can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluoxetine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Fluoxetine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Fluoxetine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Fluoxetine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluoxetine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fluoxetine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Fluoxetine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluoxetine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Fluoxetine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluoxetine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fluoxetine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Fluoxetine.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Fluoxetine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fluoxetine.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Fluoxetine.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Fluoxetine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Fluoxetine.
LevorphanolLevorphanol may increase the serotonergic activities of Fluoxetine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluoxetine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluoxetine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluoxetine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluoxetine.
LinezolidLinezolid may increase the serotonergic activities of Fluoxetine.
LinezolidThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fluoxetine.
LiraglutideFluoxetine may increase the hypoglycemic activities of Liraglutide.
LisurideThe metabolism of Lisuride can be decreased when combined with Fluoxetine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fluoxetine.
LofentanilLofentanil may increase the serotonergic activities of Fluoxetine.
LomustineThe metabolism of Lomustine can be decreased when combined with Fluoxetine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fluoxetine.
LopinavirFluoxetine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluoxetine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluoxetine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluoxetine.
LorcaserinThe metabolism of Fluoxetine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.
LosartanThe metabolism of Fluoxetine can be decreased when combined with Losartan.
LovastatinThe metabolism of Fluoxetine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluoxetine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Fluoxetine.
Lu AA21004Fluoxetine may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Fluoxetine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Fluoxetine can be decreased when it is combined with Lumacaftor.
LumefantrineFluoxetine may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Fluoxetine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluoxetine.
MacitentanThe metabolism of Macitentan can be decreased when combined with Fluoxetine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fluoxetine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Fluoxetine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluoxetine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Fluoxetine.
MebanazineMebanazine may increase the serotonergic activities of Fluoxetine.
MecaserminFluoxetine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluoxetine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluoxetine.
MefloquineMefloquine may increase the QTc-prolonging activities of Fluoxetine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluoxetine.
MelatoninThe metabolism of Melatonin can be decreased when combined with Fluoxetine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fluoxetine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluoxetine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluoxetine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluoxetine.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Fluoxetine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Fluoxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluoxetine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.
MetforminFluoxetine may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the QTc-prolonging activities of Fluoxetine.
MethadoneThe metabolism of Methadone can be decreased when combined with Fluoxetine.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Fluoxetine.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Fluoxetine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluoxetine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluoxetine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluoxetine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluoxetine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluoxetine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluoxetine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluoxetine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluoxetine.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Fluoxetine.
MethyclothiazideFluoxetine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueFluoxetine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Fluoxetine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluoxetine.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Fluoxetine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Fluoxetine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.
MetolazoneFluoxetine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.
MetoprololThe metabolism of Fluoxetine can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Fluoxetine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluoxetine.
MianserinThe metabolism of Mianserin can be decreased when combined with Fluoxetine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluoxetine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fluoxetine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Fluoxetine.
MiglitolFluoxetine may increase the hypoglycemic activities of Miglitol.
MilnacipranFluoxetine may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Fluoxetine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Fluoxetine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Fluoxetine.
MirabegronThe metabolism of Fluoxetine can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mirtazapine.
MitotaneThe serum concentration of Fluoxetine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluoxetine.
MoclobemideMoclobemide may increase the serotonergic activities of Fluoxetine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluoxetine.
ModafinilThe serum concentration of Fluoxetine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Fluoxetine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluoxetine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fluoxetine.
MorphineMorphine may increase the serotonergic activities of Fluoxetine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Fluoxetine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Fluoxetine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluoxetine.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fluoxetine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.
NafcillinThe serum concentration of Fluoxetine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Fluoxetine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluoxetine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fluoxetine.
NaratriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Naratriptan.
NateglinideFluoxetine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.
NefazodoneThe metabolism of Fluoxetine can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Fluoxetine.
NelfinavirThe metabolism of Fluoxetine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Fluoxetine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Fluoxetine.
NevirapineThe metabolism of Fluoxetine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Fluoxetine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fluoxetine.
NicardipineThe metabolism of Fluoxetine can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Fluoxetine.
NicotineThe metabolism of Nicotine can be decreased when combined with Fluoxetine.
NifedipineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nifedipine.
NilotinibFluoxetine may increase the QTc-prolonging activities of Nilotinib.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Fluoxetine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluoxetine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluoxetine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Fluoxetine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluoxetine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluoxetine.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Fluoxetine.
NormethadoneNormethadone may increase the serotonergic activities of Fluoxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluoxetine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Fluoxetine.
OctamoxinOctamoxin may increase the serotonergic activities of Fluoxetine.
OctreotideFluoxetine may increase the hypoglycemic activities of Octreotide.
OctreotideOctreotide may increase the QTc-prolonging activities of Fluoxetine.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Fluoxetine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluoxetine.
OlaparibThe metabolism of Fluoxetine can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Fluoxetine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluoxetine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluoxetine.
OmeprazoleThe metabolism of Fluoxetine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ondansetron.
OndansetronOndansetron may increase the QTc-prolonging activities of Fluoxetine.
OpiumOpium may increase the serotonergic activities of Fluoxetine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluoxetine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluoxetine.
OsimertinibThe serum concentration of Fluoxetine can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Fluoxetine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluoxetine.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Fluoxetine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluoxetine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluoxetine.
OxycodoneOxycodone may increase the serotonergic activities of Fluoxetine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Fluoxetine.
OxymorphoneOxymorphone may increase the serotonergic activities of Fluoxetine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Fluoxetine.
OxytocinOxytocin may increase the QTc-prolonging activities of Fluoxetine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fluoxetine.
PalbociclibThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.
PaliperidoneFluoxetine may increase the QTc-prolonging activities of Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Fluoxetine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Fluoxetine.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Fluoxetine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Fluoxetine.
PantoprazoleThe metabolism of Fluoxetine can be decreased when combined with Pantoprazole.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluoxetine.
PargylinePargyline may increase the serotonergic activities of Fluoxetine.
ParoxetineFluoxetine may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Fluoxetine can be decreased when combined with Paroxetine.
PasireotideFluoxetine may increase the hypoglycemic activities of Pasireotide.
PasireotidePasireotide may increase the QTc-prolonging activities of Fluoxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.
PazopanibPazopanib may increase the QTc-prolonging activities of Fluoxetine.
Peginterferon alfa-2bThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Fluoxetine.
PentamidineFluoxetine may increase the hypoglycemic activities of Pentamidine.
PentamidinePentamidine may increase the QTc-prolonging activities of Fluoxetine.
PentazocinePentazocine may increase the serotonergic activities of Fluoxetine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluoxetine.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Fluoxetine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluoxetine.
PerflutrenPerflutren may increase the QTc-prolonging activities of Fluoxetine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Fluoxetine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluoxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluoxetine.
PethidinePethidine may increase the serotonergic activities of Fluoxetine.
PethidineThe metabolism of Pethidine can be decreased when combined with Fluoxetine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluoxetine.
PhenelzinePhenelzine may increase the serotonergic activities of Fluoxetine.
PhenelzineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Fluoxetine.
PhenindioneFluoxetine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Fluoxetine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluoxetine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Fluoxetine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fluoxetine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fluoxetine.
PhenprocoumonFluoxetine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluoxetine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluoxetine.
PimozideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Pimozide.
PimozidePimozide may increase the QTc-prolonging activities of Fluoxetine.
PindololThe serum concentration of Pindolol can be increased when it is combined with Fluoxetine.
PioglitazoneFluoxetine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluoxetine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Fluoxetine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluoxetine.
PirlindolePirlindole may increase the serotonergic activities of Fluoxetine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluoxetine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Fluoxetine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fluoxetine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Fluoxetine.
PolythiazideFluoxetine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluoxetine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluoxetine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fluoxetine.
PosaconazoleThe metabolism of Fluoxetine can be decreased when combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.
PramlintideFluoxetine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluoxetine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluoxetine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Fluoxetine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluoxetine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fluoxetine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluoxetine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluoxetine.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Fluoxetine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fluoxetine.
PrimidoneThe metabolism of Primidone can be decreased when combined with Fluoxetine.
ProcainamideFluoxetine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluoxetine.
ProcarbazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluoxetine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Fluoxetine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluoxetine.
PromazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Promazine.
PromazinePromazine may increase the QTc-prolonging activities of Fluoxetine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluoxetine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Fluoxetine.
PropafenonePropafenone may increase the QTc-prolonging activities of Fluoxetine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Fluoxetine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluoxetine.
PropericiazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluoxetine.
PropofolThe metabolism of Propofol can be decreased when combined with Fluoxetine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fluoxetine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fluoxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluoxetine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fluoxetine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Fluoxetine.
PyrimethamineThe metabolism of Fluoxetine can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Fluoxetine can be increased when it is combined with Quazepam.
QuazepamThe metabolism of Quazepam can be decreased when combined with Fluoxetine.
QuetiapineFluoxetine may increase the QTc-prolonging activities of Quetiapine.
QuinethazoneFluoxetine may increase the hyponatremic activities of Quinethazone.
QuinidineFluoxetine may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the QTc-prolonging activities of Fluoxetine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Fluoxetine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fluoxetine.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Fluoxetine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fluoxetine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluoxetine.
RanolazineThe metabolism of Fluoxetine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Fluoxetine.
RasagilineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Fluoxetine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluoxetine.
RepaglinideFluoxetine may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Fluoxetine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluoxetine.
RifabutinThe metabolism of Fluoxetine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Fluoxetine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Fluoxetine.
RifapentineThe metabolism of Fluoxetine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluoxetine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Fluoxetine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fluoxetine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluoxetine.
RitonavirThe metabolism of Fluoxetine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Fluoxetine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fluoxetine.
RizatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rizatriptan.
RolapitantThe metabolism of Fluoxetine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fluoxetine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluoxetine.
RopiniroleThe metabolism of Fluoxetine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluoxetine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Fluoxetine.
RosiglitazoneFluoxetine may increase the hypoglycemic activities of Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluoxetine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Fluoxetine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluoxetine.
SafrazineSafrazine may increase the serotonergic activities of Fluoxetine.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Fluoxetine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fluoxetine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Fluoxetine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Fluoxetine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Fluoxetine.
SaxagliptinFluoxetine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluoxetine.
SelegilineSelegiline may increase the serotonergic activities of Fluoxetine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Fluoxetine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fluoxetine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluoxetine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fluoxetine.
SertralineThe metabolism of Fluoxetine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluoxetine.
SildenafilThe metabolism of Fluoxetine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.
SiltuximabThe serum concentration of Fluoxetine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Fluoxetine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Fluoxetine.
SitagliptinFluoxetine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fluoxetine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluoxetine.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Fluoxetine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Fluoxetine.
SorafenibThe metabolism of Fluoxetine can be decreased when combined with Sorafenib.
SotalolFluoxetine may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fluoxetine.
SparteineThe metabolism of Sparteine can be decreased when combined with Fluoxetine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluoxetine.
St. John's WortThe serum concentration of Fluoxetine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Fluoxetine.
SufentanilSufentanil may increase the serotonergic activities of Fluoxetine.
SulfadiazineFluoxetine may increase the hypoglycemic activities of Sulfadiazine.
SulfadiazineThe metabolism of Fluoxetine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleFluoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleThe metabolism of Fluoxetine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleFluoxetine may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Fluoxetine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluoxetine.
SumatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sumatriptan.
SunitinibFluoxetine may increase the hypoglycemic activities of Sunitinib.
SunitinibSunitinib may increase the QTc-prolonging activities of Fluoxetine.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fluoxetine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fluoxetine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluoxetine resulting in a loss in efficacy.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Fluoxetine.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.
TapentadolTapentadol may increase the serotonergic activities of Fluoxetine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Fluoxetine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fluoxetine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluoxetine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluoxetine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluoxetine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Fluoxetine.
TelaprevirThe metabolism of Fluoxetine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Fluoxetine.
TelavancinTelavancin may increase the QTc-prolonging activities of Fluoxetine.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Fluoxetine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluoxetine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluoxetine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fluoxetine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Fluoxetine.
TenofovirThe metabolism of Fluoxetine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Fluoxetine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Fluoxetine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluoxetine.
TeriflunomideThe serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Fluoxetine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluoxetine.
TetrabenazineFluoxetine may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluoxetine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluoxetine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluoxetine.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Fluoxetine.
TheophyllineThe metabolism of Fluoxetine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluoxetine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluoxetine.
ThioproperazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluoxetine.
ThioridazineThioridazine may increase the QTc-prolonging activities of Fluoxetine.
ThiotepaThe metabolism of Fluoxetine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluoxetine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluoxetine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluoxetine.
TianeptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tianeptine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fluoxetine.
TicagrelorThe metabolism of Fluoxetine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Fluoxetine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluoxetine.
TimololThe serum concentration of Timolol can be increased when it is combined with Fluoxetine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Fluoxetine.
TipranavirThe metabolism of Fluoxetine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluoxetine.
TocilizumabThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Fluoxetine.
TolazamideFluoxetine may increase the hypoglycemic activities of Tolazamide.
TolbutamideFluoxetine may increase the hypoglycemic activities of Tolbutamide.
TolbutamideThe metabolism of Fluoxetine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.
ToloxatoneToloxatone may increase the serotonergic activities of Fluoxetine.
TolterodineTolterodine may increase the QTc-prolonging activities of Fluoxetine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Fluoxetine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluoxetine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluoxetine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluoxetine.
ToremifeneFluoxetine may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Fluoxetine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Fluoxetine.
TramadolTramadol may increase the serotonergic activities of Fluoxetine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fluoxetine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Fluoxetine.
TranylcypromineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fluoxetine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluoxetine.
TrazodoneFluoxetine may increase the serotonergic activities of Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Fluoxetine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluoxetine.
TrichlormethiazideFluoxetine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluoxetine.
TrimethoprimThe metabolism of Fluoxetine can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluoxetine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Fluoxetine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluoxetine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Fluoxetine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluoxetine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fluoxetine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fluoxetine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluoxetine.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Fluoxetine.
ValsartanThe metabolism of Fluoxetine can be decreased when combined with Valsartan.
VandetanibFluoxetine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Fluoxetine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fluoxetine.
VemurafenibFluoxetine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Fluoxetine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Fluoxetine.
VerapamilThe metabolism of Fluoxetine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Fluoxetine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluoxetine.
VilanterolVilanterol may increase the QTc-prolonging activities of Fluoxetine.
VilazodoneFluoxetine may increase the serotonergic activities of Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fluoxetine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluoxetine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Fluoxetine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fluoxetine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Fluoxetine.
VorinostatVorinostat may increase the QTc-prolonging activities of Fluoxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fluoxetine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Fluoxetine.
WarfarinFluoxetine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluoxetine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Fluoxetine.
ZafirlukastThe metabolism of Fluoxetine can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluoxetine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluoxetine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluoxetine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fluoxetine.
ZimelidineFluoxetine may increase the serotonergic activities of Zimelidine.
ZiprasidoneFluoxetine may increase the QTc-prolonging activities of Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluoxetine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluoxetine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluoxetine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Fluoxetine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluoxetine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluoxetine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fluoxetine.
ZuclopenthixolFluoxetine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation and nausea.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Richman A, Heinrichs SC: Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation. Epilepsy Res. 2007 Apr;74(1):19-27. Epub 2007 Jan 9. [PubMed:17215106 ]
  2. Iceta R, Mesonero JE, Alcalde AI: Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci. 2007 Mar 27;80(16):1517-24. Epub 2007 Jan 20. [PubMed:17289086 ]
  3. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  4. Sanders AC, Hussain AJ, Hen R, Zhuang X: Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology. 2007 Nov;32(11):2321-9. Epub 2007 Mar 14. [PubMed:17356573 ]
  5. Goren MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B: Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res. 2007 Sep;32(9):1559-65. Epub 2007 May 8. [PubMed:17486443 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  4. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  5. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40